HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nuñez, L. Articles by Larrea, J. L. Search for Related Content PubMed PubMed Citation Articles by Nuñez, L. Articles by Larrea, J. L.

Ann Thorac Surg 1982;33:354-358
© 1982 The Society of Thoracic Surgeons

---

Articles

Aspirin or Coumadin as the Drug of Choice for Valve Replacement with Porcine Bioprosthesis

From the Department of Cardiac Surgery, Ciudad Sanitaria "La Paz" Autonomous University of Madrid, Madrid, Spain.

Accepted for publication June 8, 1981.

^* Address reprint requests to Dr. Nuñez, Cardiac Surgery, C/ Otero y Delage, 58, Madrid, 35, Spain.

Eight hundred twenty-four patients who had cardiac valve replacement with a porcine bioprosthesis were given either Coumadin (sodium warfarin) or aspirin. No patient in sinus rhythm no matter what valve or valves were replaced had thromboembolism whether treated with Coumadin (124 patients) or aspirin (260 patients). One hundred fifty-one patients who had mitral valve replacement, were in atrial fibrillation, and were treated with Coumadin had seven embolic events (4.6%), while 135 similar patients treated with aspirin had five embolic events (3.7%). Fifty-one patients who had double-valve replacement, were in atrial fibrillation, and were treated with Coumadin had three embolic episodes (5.9%), while 86 similar patients treated with aspirin had three embolic events (3.5%).

No statistical difference was found in the incidence of thromboembolism between similar groups of patients whether treated with Coumadin or aspirin (p > 0.05). Hemorrhagic complications were higher and reached statistical significance (p < 0.001) for the group treated with Coumadin. This study shows that aspirin prevents thromboembolic complications as well as Coumadin in patients having cardiac valve replacement with a bioprosthesis, and results in a lower rate of complications.

This article has been cited by other articles:

				F. di Marco, S. Grendene, G. Feltrin, D. Meneghetti, and G. Gerosa Antiplatelet therapy in patients receiving aortic bioprostheses: A report of clinical and instrumental safety J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1597 - 1603. [Abstract] [Full Text] [PDF]

				F. di Marco, M. Giordan, and G. Gerosa Early antithrombotic therapy after aortic valve replacement with tissue valves: When the practice diverges from the guidelines J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1223 - 1223. [Full Text] [PDF]

				T. E. David, S. Armstrong, and Z. Sun The Hancock II bioprosthesis at ten years Ann. Thorac. Surg., August 1, 1995; 60(suppl_2): S229 - S234. [Abstract] [PDF]

				L. H. Edmunds Jr. Thrombotic and Bleeding Complications of Prosthetic Heart Valves Ann. Thorac. Surg., October 1, 1987; 44(4): 430 - 445. [Abstract] [PDF]

				T. E. David, W. I. C. Ho, and G. T. Christakis Thromboembolism in Patients with Aortic Porcine Bioprostheses Ann. Thorac. Surg., September 1, 1985; 40(3): 229 - 233. [Abstract] [PDF]

				L. Nunez, M. G. Aguado, J. L. Larrea, D. Celemin, and J. Oliver Prevention of Thromboembolism Using Aspirin after Mitral Valve Replacement with Porcine Bioprosthesis Ann. Thorac. Surg., January 1, 1984; 37(1): 84 - 87. [Abstract] [PDF]